ScreenerHero

KALV KalVista Pharmaceuticals, Inc.

Partial data
NAS · US · Healthcare · Biotechnology · kalvista.com
27.00USD0.00%Mkt Cap: 1.44B $P/E: —

As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.44B USD
Enterprise Value1.44B USD
Revenue (TTM)114.48M USD
Gross Profit58.47M USD
Net Income (TTM)-183.44M USD
Revenue/Share2.11 USD
Last Price27.00 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees275
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS4834971032
Valuation
P/E (Trailing)—
P/E (Forward)17.48
PEG—
EV/EBITDA-10.38
EV/Revenue12.55
P/S12.56
P/B—
EPS (TTM)-3.94
EPS (Forward)1.71
52W Range
9.830100% of range27.00
52W High27.00 USD
52W Low9.830 USD
Profitability
Gross Margin51.07%
Oper. Margin-57.37%
EBITDA Margin-120.94%
Profit Margin-118.74%
ROE6766.65%
ROA-54.70%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-152.91M USD
CapEx (TTM)929.00K USD
FCF Margin—
FCF Yield—
Net Debt-718.02K USD
Net Debt/EBITDA0.01
Balance Sheet
Debt/Equity-55.91
Current Ratio5.17
Quick Ratio4.97
Book Value/Sh-0.38 USD
Cash/Share5.35 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:14
Split DateNov 22, 2016
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)27.00 USD
Upside (mean)+0.0%
Target Range27.00 USD – 27.00 USD
# Analysts3
Ownership
Shares Out.53.24M
Float38.18M
Insiders1.72%
Institutions136.88%
Short Interest
Short Ratio0.9d
Short % Float14.37%
Short % Out.12.85%
Shares Short6.84M
Short (prev mo.)15.16M
Technical
SMA 5024.43 (+10.5%)
SMA 20017.09 (+58.0%)
Beta-0.11
S&P 52W Chg13.94%
Avg Vol (30d)3.38M
Avg Vol (10d)2.09M
Technical Indicators
RSI (14)76.3
MACD0.7269
MACD Signal0.9492
MACD Hist.-0.2223
BB Upper27.06 USD
BB Middle26.86 USD
BB Lower26.66 USD
BB Width1.49%
ATR (14)0.2178 USD
Vol Ratio (20d)0.00x